Getty Images
Lilly Rolls Out Personalized Diabetes Management Platform
In a recent press release, Lilly announced that it plans to roll out its personalized diabetes management platform to help patients and providers make informed, data-backed clinical decisions.
On November 7, 2022, Eli Lilly announced the rollout of Tempo, the company’s personalized diabetes management platform. According to the press release, the platform is intended to help patients and providers make informed clinical decisions backed by data. The CDC states that nearly 11.3% of the United States population has diabetes, approximately 37.3 million people.
Diabetes is associated with multiple complications, including kidney disease, visual impairments, and, in some cases, death. The best way to prevent or minimize the related complications of the disease is to manage the chronic condition as well as possible.
The Tempo platform will include the Tempo Smart Button, TempoSmart — an app, and a prefilled insulin pen. The Tempo Smart Button is an FDA-approved device that detects, stores, and transfers information on insulin doses.
The press release states, “Here's how the platform works: The Tempo Smart Button is a reusable medical device that attaches to the top of a Tempo Pen ― Lilly's prefilled, disposable insulin pens approved in 2019 and 2020. When paired via Bluetooth wireless technology, the Smart Button is intended to detect, store, and transfer insulin dose-related data to the compatible app. The app, TempoSmart, will record insulin dose information and facilitate data sharing between adults with diabetes and the healthcare providers who treat them.”
Additionally, healthcare providers can access patient data and track patient progress through the clinician hub called Tempo Insights. For patients, the app can be set up to give medication reminders, educational resources, and feedback on blood glucose levels. Patients can also connect the app with the Dexcom Continuous Glucose Monitoring System, Fitbit, the Apple Health app, and other wearable devices.
“Despite technological advancements, people continue to experience challenges with the complexities of insulin dosing," said Kevin Cammack, Head of Connected Care, Lilly Diabetes, in the press release. "Using the learnings from early adopters of Tempo, we look forward to continually innovating our technology to aid those who use Lilly insulins to manage their diabetes."
As the popularity of personalized medicine grows, this platform may be helpful to many clinicians and patients. While the impacts of this tool have not yet been seen, it has the potential to minimize the strains and side effects of this chronic disease.
